Medical Device and Pharma Innovation
The United States has the most technologically advanced medical devices and pharmaceutical products in the world. New medical devices that improve existing therapies or introduce a new therapy are continually being introduced, as are new new and innovative pharmaceutical products that fill a need for a new treatment or improve existing treatments.
And though innovation thrives in the U.S., there is a regulatory framework in place to ensure that medical devices and pharmaceuticals placed on the market are safe and effective. This means that manufacturers of moderate- to high-risk devices and drugs must demonstrate that their new or modified product is safe and effective before receiving FDA marketing approval or clearance.
New Drugs and Devices
New pharmaceutical products must prove their safety and efficacy through the FDA’s traditional approval process or its Accelerated Approval program. Read more.
New medical devices are approved for marketing based on FDA regulations to enforce the Medical Device Amendments (MDAs) of the Food, Drug and Cosmetic Act. Devices are classified and approved based on established marketing approval tracks, such as Pre-Market Notification, also known as 510(k) and Pre-Market Approval (PMA). Read more.
Innovation Headlines
FDA Approves Novel Device for Pancreatic Cancer Treatment
FDA Approves Novel Device for Pancreatic Cancer Treatment The U.S. Food and Drug Administration has approved Optune Pax, a first-of-its-kind medical device designed to treat adult patients with locally advanced pancreatic cancer. Developed by Novocure, the portable...
FDA “PreCheck” Program to Boost U.S. Drug Manufacturing
FDA Announces New PreCheck Drug Manufacturing Program The U.S. Food and Drug Administration (FDA) has announced the launch of FDA PreCheck, a groundbreaking new program designed to strengthen America’s domestic pharmaceutical supply chain by streamlining the...
The FDA Orphan Drug Program
Incentives for Rare Disease Drug Development The FDA’s Orphan Drug Program was established to encourage the development of drugs for rare diseases that affect fewer than 200,000 people in the U.S. Because these diseases often lack market incentives due to small...
FDA Grants Accelerated Approval to Multiple Myeloma Treatment
For hard-to-treat multiple myeloma On July 2, 2025, the FDA granted accelerated approval to linvoseltamab-gcpt (brand name: Lynozyfic) for adults with relapsed or refractory multiple myeloma who have received at least four prior therapies, including: A proteasome...
FDA Approves Alhemo for Patients with Hemophilia A or B
For Patients with Hemophilia A or B with Inhibitors The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with: Hemophilia A with factor VIII inhibitors, or Hemophilia B with factor...
First-in-Class Non-Opioid Pain Reliever: Journavx
A new non-opioid pain treatment option On January 30, 2025, the FDA granted priority review for Journavx (suzetrigine) – a first-in-class, non-opioid analgesic for treating moderate to severe acute pain in adults. How It Works Journavx targets sodium channels in the...
FDA Approves DATROWAY® Breast Cancer Treatment
A new breast cancer treatment option The United States Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) on January 17, 2025, for adults with hormone receptor-positive (HR+), HER2-negative breast cancer that is unresectable or...
Human Factors Engineering
Human Factors Engineering Human Factors Engineering (HFE) is critical for medical device safety and regulatory compliance, especially for Class II and III devices, drug-delivery systems, and combination products. Following is a detailed breakdown of the regulatory...
Generic Eliquis
Generic Eliquis Editor's note: FDA originally announced the approval of generic equivalents to Eliquis in 2019, and updated that information the next year. We are publishing this information as a response to reader requests for more information about generic Eliquis....
FDA Grants Accelerated Approval to Tarlatamab-dlle
Treatment for lung cancer with progression following platinum-based chemotherapy On May 16, 2024, the Food and Drug Administration (FDA) granted accelerated approval to Imdelltra (tarlatamab-dlle) manufactured by Amgen, Inc. for the treatment of extensive stage small...